Study to Assess Mechanisms in Peripheral Tissue Innervation for Fibromyalgia

Fibromyalgia Clinical Trial

Official title:

Duloxetine(Cymbalta) for Fibromyalgia: An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Duloxetine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01127490
• Other study ID #: DUL2009-FFMS
• Status: Completed
• Phase: N/A
• Start date: May 5, 2010
• Est. completion date: September 9, 2015

Study information

• Verified date: January 2020
• Source: Albany Medical College
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to examine the characteristics of the nerves and the small veins in the skin of people with fibromyalgia. The investigators will then use this information to identify possible processes in the skin that may help explain why some people feel pain relief with the study drug (duloxetine) and others do not.

Duloxetine affects certain chemicals in the brain called neurotransmitters. An abnormality in these chemicals is thought to be related to fibromyalgia. Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the treatment of depression. Duloxetine is approved for sale in the United States by the Food and Drug Administration (FDA) for the treatment of fibromyalgia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: September 9, 2015
• Est. primary completion date: September 9, 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Female age 18-70

• Fulfill the ACR criteria for FMS (wide spread pain for at least 3 months and pain in at least 11 of 18 tender point sites.

• VAS score greater than 40mm at Screening and Randomization Visits

Exclusion Criteria:

• History of clinically significant liver disease, serious peripheral vascular disease, a blood clotting disorder, or any other medical condition felt to be exclusionary by the investigator

• Allergy to lidocaine

• Unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study.

• Women who are pregnant, breastfeeding or trying to become pregnant

• Active cancer within the previous two years except treated basal cell carcinoma of the skin

• Presence of dermatological or neurological condition that could interfere with the interpretation of the skin biopsy or QST

• Co-existing conditions that can produce chronic widespread pain

• Presence of uncontrolled or severe depression

• Patients with pending Worker's Compensation, worker's Compensation, any ongoing litigation or disability claims due to fibromyalgia or any other source of pain, or currently receiving monetary compensation as a result of any of the above.

• Presence of uncontrolled narrow-angle glaucoma

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Drug:
• Duloxetine
Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.

Procedure:
• Skin biopsy
3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand

Locations

Country	Name	City	State
United States	Neurosciences Institute, Albany Medical College	Albany	New York

Sponsors (1)

Lead Sponsor	Collaborator
Albany Medical College

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of duloxetine will be determined by neurological and pain assessments.	Patients will be evaluated prior to being started on duloxetine and again at eight weeks. We will use data from VAS scores, sleep diaries and quantative sensory testing.	9 weeks